Du är nu på väg att lämna en GSK-hemsida

Denna länk leder till en hemsida som inte tillhör GSK. GSK tar inget ansvar för innehållet på tredje parts hemsidor.

Fortsätt

Tillbaka

How to prescribe Tivicay?

Gå till Stäng Överst

Convenience beyond once-daily dosing

TIVICAY (dolutegravir) is a once-daily, unboosted integrase inhibitor indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children above 6 years of age. 1

  • Small tablet size
  • Can be taken with or without food 1**
  • No time-of-day restrictions 1
  • No boosting required 1
  • Few significant DDIs with commonly used medications 12

Dosing recommendations 1

Available tablet strengths 1

  • 10 mg film-coated tablets: white, round, biconvex tablets approximately 6 mm in diameter
  • 25 mg film-coated tablets: pale yellow, round, biconvex tablets approximately 7 mm in diameter
  • 50 mg film-coated tablets: yellow, round, biconvex tablets approximately 9 mm in diameter

Contraindications 1

Hypersensitivity to the active substance or to any of the excipients. Co-administration with dofetilide.
 

For further information, please see Tivicay prescribing information

This medicinal product is subject to additional monitoring.

*Must be taken in combination with other antiretroviral agents. 1
**In the presence of INI class resistance, TIVICAY should preferably be taken with food to enhance exposure (particularly in patients with Q148 mutations). 1
In the presence of integrase inhibitor resistance, there are insufficient data to recommend a dose for dolutegravir in adolescents and children. 1

References:

  1. TIVICAY (dolutegravir) Summary of Product Characteristics, February 2017.
  2. Kandel CE, Walmsley S. Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV. Drug Design, Development and Therapy. 2015:9 3547-3555.

TIVICAY is a registered trademark of the ViiV Healthcare group of companies.